Belgian-based Aminolabs Nutrition has announced the strategic acquisition of Zoka Pharma, a Valencia-based producer of nutritional supplements, in a move to expand its European footprint and diversify its product offerings.
Zoka Pharma brings a strong product portfolio – including gels, liquids, probiotics, infant nutrition, and pet supplements – alongside enhanced production infrastructure to Aminolabs.
The acquisition also increases Aminolabs’ manufacturing capacity in core formats such as tablets, capsules, and stick packs, enabling faster and more flexible delivery to meet growing market demand.
Zoka currently generates 11 million euros in revenue from two modern facilities, supported by around 50 employees. With just 30 percent of its capacity utilized, the company offers significant room for growth. Its goal is to double Spanish turnover to 20 million euros within two years.
“This is more than a business decision — it’s a powerful synergy of capabilities and values”, says Roger Anné, Founder of Aminolabs. “Zoka Pharma shares our entrepreneurial mindset and commitment to quality. Together, we can serve customers better and grow faster in the booming health and nutrition market.”
The acquisition, supported by Alantra, marks Aminolabs’ first step in a broader expansion strategy aimed at strengthening its presence across Europe and entering markets in North Africa and the Middle East. This move follows Aminolabs’ 2023 management buyout from Waterland Private Equity, with strategic support from LRM, and aligns with the company’s plan to reach a 150 million euros group turnover within two years.
